U P-glycoprotein polymorphism and levothyroxine bioavailability in hypothyroid patients


Oztas E. , Garcia-Saavedra A. P. , Yanar F., Ozcinar B. , Aksakal N., Purisa S., et al.

SAUDI PHARMACEUTICAL JOURNAL, cilt.26, ss.274-278, 2018 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Cilt numarası: 26 Konu: 2
  • Basım Tarihi: 2018
  • Doi Numarası: 10.1016/j.jsps.2017.11.012
  • Dergi Adı: SAUDI PHARMACEUTICAL JOURNAL
  • Sayfa Sayısı: ss.274-278

Özet

Objectives: P-glycoprotein (P-gp) contributes to the disposition of a wide variety of drugs; therefore, single nucleotide polymorphisms (SNPs) in the P-gp coding gene might affect its activity. It is well known that personalized medicine, instead of empirical treatment, is a clinically important approach for enhancing responses among patients. Indeed, there is a need to evaluate the association between SNPs of P-gp encoded multidrug resistance genes (MDR1, ABCB1), and the dosage requirements of these drugs. In the present study, we evaluated the association between the dosage of Levothyroxine (L-T4) and three common SNPs (C1236T, G2677T/A and C3435T).